FRIDAY, Sept. 9, 2022 (HealthDay News) — People wanting to maintain wrinkles at bay will quickly have a brand new choice now that the U.S. Food and Drug Administration has authorised the primary competitor for Botox in a long time.

Daxxify, made by Revance Therapeutics Inc. in Nashville, Tenn., is injected into the face alongside fear traces. It lasts longer than Botox, with about 80% of customers seeing no or delicate facial traces at 4 months after injection. For half of customers, the remedy lasted six months, the corporate mentioned in an announcement.

“Users do not have to go once every three months,” Dr. Balaji Prasad, who covers specialty prescription drugs as an analyst for Barclays Investment Bank, advised the New York Times. “In a world where time is of the essence, having a product with a long duration factor is extremely useful.”

The new drug now enters the $3 billion subject of facial injection medication. It can also be a neuromuscular blocking agent and a botulinum toxin, like Abbvie’s Botox.

“It also opens up the door for what we can do with therapeutics,” mentioned Revance CEO Mark Foley, advised the Times. “If you think of migraines, cervical dystonia [a neurological condition that affects the muscles in the neck and shoulders], overactive bladder, there’s a huge medical opportunity as well.”

The firm has begun testing the drug on these different medical points, Foley mentioned. While the corporate had been attempting to create a product that wanted no needle, it as a substitute found a means to make use of peptide know-how to maintain the product secure. Typically, animal protein or human serum is used.

Botox can also be used for extra than simply wrinkles. It has been an FDA-approved remedy for continual migraines since 2010.

Users of Daxxify within the Revance research included some who skilled unwanted side effects. About 2% of individuals developed a drooping eyelid, whereas about 6% skilled headache, the corporate mentioned.

Toxin-based remedy can carry the potential for different unwanted side effects, resembling common muscle weak spot or respiration difficulties, the FDA cautioned. Daxxify examine members confirmed none of these signs.

Revance had initially hoped for approval of its product in November 2020, however plans had been postponed due to pandemic journey restrictions, the Times reported. An inspection lastly performed in June 2021 discovered issues with the standard management course of and the corporate’s working cell financial institution, which include the drug’s energetic ingredient. Those issues had been resolved, the Times reported.

More data

The National Library of Medicine has extra about botulinum toxin.

The post FDA Approves Botox Competitor That Lasts Longer appeared first on Healthy and Slim Life.

By Cara Murez and Robin Foster HealthDay Reporters

HealthDay Reporter

TUESDAY, April 26, 2022 (HealthDay News) – The U.S. Food and Drug Administration on Tuesday accepted the antiviral remdesivir as the primary COVID-19 remedy for younger youngsters.

The drug had up to now solely been obtainable to this age group below a particular FDA emergency use authorization order.

Now, medical doctors treating youngsters below 12 who’re hospitalized or are at dwelling with mild-to-moderate COVID however a excessive danger for extreme COVID can readily prescribe Veklury (remdesivir) to their younger sufferers. Remdesivir had already been totally accepted to deal with individuals 12 and older.

“As COVID-19 may cause extreme sickness in youngsters, a few of whom don’t at the moment have a vaccination choice, there continues to be a necessity for protected and efficient COVID-19 remedy choices for this inhabitants,” Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, stated in an company information launch.

“Today’s approval of the primary COVID-19 therapeutic for this inhabitants demonstrates the company’s dedication to that want.”

In a information launch from drug maker Gilead Sciences, one pediatric infectious illnesses physician welcomed the information.

“This approval means that remdesivir can potentially provide meaningful clinical improvement, by reducing disease progression and helping children recover from COVID-19 more quickly,” stated Dr. Amina Ahmed, from Atrium Health-Levine Children’s Hospital in Charlotte, N.C. “We need proven antiviral treatment options, like remdesivir, that can help treat some of the most vulnerable in our society: children.”

The FDA famous that Veklury isn’t an alternative choice to getting a vaccination, though there’s not but a vaccine accepted for kids aged 4 and youthful. Two COVID vaccines, Pfizer and Moderna, have been totally accepted and three can be found for emergency use, relying on age. The vaccines are supposed to stop critical scientific outcomes, together with hospitalization and dying, the FDA stated. People also needs to obtain a booster, if eligible, the company added.

The approval was primarily based on outcomes from a section 3 scientific trial for adults, the FDA stated, noting that the course of the illness is comparable in each grownup and pediatric sufferers.

Continued

It can be supported by a section 2/3 scientific research of 53 pediatric sufferers, the FDA stated. Patients in that research had a confirmed COVID an infection starting from gentle to extreme and obtained the treatment for 10 days. Results, together with security outcomes, have been just like these already seen in adults, the company stated.

Possible unwanted side effects of the drug, which may solely be delivered by way of injection, embody elevated ranges of liver enzymes, which can be an indication of liver damage; and allergic reactions, which can embody adjustments in blood stress and coronary heart charge, low blood oxygen degree, fever, shortness of breath, wheezing, swelling, rash, nausea, sweating or shivering.

More info

The U.S. Centers for Disease Control and Prevention has extra on COVID-19.

SOURCE: U.S. Food and Drug Administration, information launch, April 25, 2022

WebMD News from HealthDay

Copyright © 2013-2022 HealthDay. All rights reserved.

The post FDA Approves First COVID Treatment for Use in Kids appeared first on Healthy and Slim Life.

Feb. 9, 2022

The Vermont legislature has permitted a constitutional modification that, if permitted by voters, would assure a lady’s reproductive rights, together with the appropriate to an abortion.

Other states have handed legal guidelines guaranteeing a lady’s proper to an abortion, however Vermont can be the primary to place that proper within the state structure, The Washington Post reported.

The reproductive rights invoice will likely be placed on the poll for the November election after the state House of Representatives handed the laws Tuesday. If permitted, it might take impact instantly.

Pew Research Center polls present Vermont residents closely assist a lady’s proper to abortion, so the modification has a superb likelihood of passing, the newspaper mentioned.

Legislatures in some states, together with Texas, have severely restricted a lady’s proper to abortion lately. Vermont abortion supporters mentioned the constitutional modification, referred to as Proposition 5, was wanted as a result of the U.S. Supreme Court is contemplating a Mississippi legislation that would overturn Roe v. Wade, the Seventies ruling that ensures a lady’s proper to abortion.

“We can no longer rely on federal courts to uphold the protections for fundamental reproductive rights based on the federal constitution,” Democratic state Rep. Ann Pugh mentioned earlier than the vote, based on The Post.

An opponent of the invoice, Republican state Rep. Anne Donahue, mentioned it assumes public opinion on abortion rights gained’t change, based on The Post.

“We as human beings have made a lot of mistakes at times when we thought we were doing the right thing,” mentioned Donahue, mentioning previous Supreme Court prior rulings on points resembling segregation. “When we start putting a current belief in the constitution, I think we’re playing with fire.”

The modification gained’t instantly make it simpler or harder for Vermont girls in search of abortions.

“What Prop 5 does mean is that the Legislature and governor will not determine what restrictions will be placed on abortion procedures,” state Rep. George Till, an obstetrician and gynecologist on the University of Vermont Medical Center, instructed The Associated Press.

The Guttmacher Institute says that Vermont “does not have any of the major types of abortion restrictions—such as waiting periods, mandated parental involvement or limitations on publicly funded abortions—often found in other states.”

In Vermont, amending the state structure requires an modification be permitted by two consecutive legislatures after which be permitted in a statewide referendum.

The modification handed each the House and Senate in 2019 and was permitted once more within the Senate in 2021, The Post reported.

The post Vermont House Approves Abortion Rights Amendment appeared first on Healthy and Slim Life.

TUESDAY, Dec. 21, 2021 (HealthDay News) — The first injection drug to stop HIV an infection was permitted by the U.S. Food and Drug Administration on Monday.

“Today’s approval adds an important tool in the effort to end the HIV epidemic by providing the first option to prevent HIV that does not involve taking a daily pill,” Dr. Debra Birnkrant, director of the Division of Antivirals within the FDA’s Center for Drug Evaluation and Research, stated in an company information launch.

Apretude (cabotegravir), made by ViiV Healthcare, was permitted to be used in at-risk adults and adolescents weighing at the very least 77 kilos, to cut back their threat of HIV. It’s first given as two injections one month aside, after which one shot is given each two months after that.

Experts welcomed the information.

“This is groundbreaking. This is game-changing. This is revolutionary,” stated Dr. David Rosenthal, medical director of the Center for Young Adult, Adolescent and Pediatric HIV at Northwell Health, in Great Neck, N.Y. “Being capable of present sufferers with HIV prevention by way of two injections each two months opens up an entire realm of potentialities.”

In an organization information launch saying the approval, Viiv CEO stated Deborah Waterhouse stated, “People who are vulnerable to acquiring HIV, especially those in Black and Latinx communities who are disproportionately impacted in the U.S., may want options beyond daily oral pills.With Apretude, people can reduce the risk of acquiring HIV with as few as six injections a year.”

Until now, two varieties of day by day capsules (Truvada and Descovy) had been the one choices for what’s known as pre-exposure prophylaxis (PrEP), however adhering to those day by day medicines to stop HIV will be troublesome, the FDA famous.

Rosenthal agreed. “We know that solely 25% of those that would profit from HIV prevention with Pre-exposure prophalaxis [PrEP] are at the moment taking it,” he famous. “Often it is because sufferers don’t wish to take medicines day by day. We’re nonetheless seeing instances of HIV within the 25-39 12 months in the past group improve, and PrEP is among the exceptional instruments we’ve to assist maintain folks protected and to allow them to take management of their sexual lives.”

The FDA’s approval of Apretude relies on two medical trials evaluating the injection drug to Truvada. The first trial included HIV-free males and transgender ladies who’ve intercourse with males and have high-risk conduct for HIV an infection, whereas the second trial concerned HIV-free ladies liable to HIV an infection.

In the primary trial, those that took Apretude had a 69% decrease threat of HIV an infection than those that took Truvada. In the second trial, those that took Apretude had a 90% decrease threat of HIV an infection than those that took Truvada, in accordance with the FDA.

Participants who took Apretude had been extra probably than those that took Truvada to have unintended effects akin to injection website reactions, headache, fever, fatigue, again ache, muscle ache and rash.

Patients who want to take Apretude can first take cabotegravir as a tablet for 4 weeks to evaluate how properly they tolerate the drug, the FDA stated.

Apretude carries a boxed warning to not use the drug except a unfavourable HIV check is confirmed.

“This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option,” Birnkrant stated.

Price may very well be a difficulty for uptake of Apretude, nonetheless.

In July, the U.S. Center for Medicare and Medicaid Services introduced that the majority insurers should cowl the 2 permitted types of PrEP capsules, Truvada and Descovy, in addition to the lab exams and clinic visits required to keep up such prescriptions. As it stands, insurers is not going to be required to cowl all prices for Apretude, which has a listing value of $3,700 per dose, NBC News reported.

More info

Visit the U.S. Centers for Disease Control and Prevention for extra on HIV/AIDS.

SOURCE: U.S. Food and Drug Administration, information launch, Dec. 21, 2021; ViiV Healthcare, information launch, Dec. 20, 2021; NBC News

The post FDA Approves First Injection Regimen for HIV Prevention appeared first on Healthy and Slim Life.